Imidazoline receptors in cardiovascular and metabolic diseases

Journal of Cardiovascular Pharmacology

Volumn 35, Issue SUPPL. 4, 2000, Pages

  Bousquet, P ^a   Dontenwill, M ^a   Greney, H ^a   Feldman, J ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Blood pressure; Brainstem; Clonidine; Imidazoline receptors; Moxonidine; Rilmenidine

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; CATECHOLAMINE; CLONIDINE; IDAZOXAN; IMIDAZOLINE; IMIDAZOLINE I1 RECEPTOR; IMIDAZOLINE I2 RECEPTOR; MOXONIDINE; RILMENIDINE;

AFFECTIVE NEUROSIS; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; BRAIN STEM; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG BINDING SITE; DRUG EFFECT; HUMAN; HYPERTENSION; INSULIN RELEASE; KIDNEY; METABOLIC DISORDER; PANCREAS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0033659293     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200000004-00004     Document Type: Review

References (75)

1. Central cardiovascular effects of α-adrenergic drugs: Difference between catecholamines and imidazolines
2. Central alpha-adrenergic systems as targets for hypotensive drugs
3. α2-Adrenoceptors: Classification, localization, mechanisms and target for drugs
4. Comparison of the effects of clonidine on pre- and postsynaptic adrenoceptors in the rabbit pulmonary artery, α-sympathomimetic inhibition of neurogenic vasoconstriction
5. Clonidine
6. 2-adrenergic effects of phenylethylamines and imidazolines
7. Evidence for direct alpha-adrenoceptor stimulation of effector neurons in cardiovascular centers by clonidine
8. Action of α-adrenergic blocking drugs on the sympathetic centres and their interactions with the central sympatho-inhibitory effect of clonidine
9. Sedative effects of a α-sympathomimetic drugs and their antagonism by adrenergic and cholinergic blocking drugs
10. 2-adrenoceptors affect sleep and arousal mechanisms
11. Localization of the central cardiovascular action of clonidine
12. The nucleus reticularis lateralis a region highly sensitive to clonidine
13. Lateral reticular formation as a site for morphine and clonidine induced hypertension
14. Clonidine-induced inhibition of sympathetic nerve activity: No indication for a central presynaptic or an indirect sympathomimetic mode of action
15. The central modulatory effect of clonidine on the cardiodepressor reflex after suppression of synthesis and storage of noradrenaline
16. The medullary cardiovascular effects of imidazolines and some GABA analogues: A review
17. Influence of central pretreatment with 6-hydroxydopamine on the hypotensive effect of clonidine
18. Role of imidazoline receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla
19. 2-adrenoceptors in the cardiovascular effects of moxonidine
20. 1-imidazoline binding site is a functional receptor mediating vasodepression via the ventral medulla
21. Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit
22. Central hypotensive effects of the α(2A)-adrenergic receptor subtype
23. On the nature of the central hypotensive effect of clonidine and α-methyldopa
24. Relative importance of medullary brain nuclei for the sympatho-inhibitory actions of rilmenidine in the anaesthetized rabbit
25. 2-adrenoceptor subtypes in mediating central effects of catecholamines and imidazolines
26. Importance of imidazoline receptors in the cardiovascular actions of centrally acting antihypertensive agents
27. Central imidazoline receptors and centrally acting antihypertensive agents
28. 125I)para-iodoclonidine reveals a new subtype of imidazoline specific sites in synaptosomal plasma membranes of the bovine brainstem
29. An endogenous clonidine-displacing substance from bovine brain: Receptor binding and hypotensive actions in the ventrolateral medulla
30. Evidence for the existence of a homogenous population of imidazoline receptors in the human brainstem
31. Evidence for imidazoline binding sixes in basolateral membranes from rabbit kidney
32. 3H)clonidine
33. 2-adrenoceptors in rabbit adipocyte membranes
34. High affinity binding of idazoxan to a non-catecholaminergic binding site in the central nervous system: Description of a putative idazoxan-receptor
35. 2-adrenoceptors in the ventro lateral medulla
36. 3H)idazoxan bind to different sites on rabbit forebrain and kidney membranes
37. 2-adrenergic receptor
38. Are there multiple imidazoline binding sites?
39. Purification and characterization of mitochondrial imidazoline-guanidinium receptive site from rabbit kidney
40. Localization of the imidazoline binding domain on monoamine oxidase B
41. 2-imidazoline sites
42. 2 sites
43. Presynaptic imidazoline receptors: New development in classification
44. Isolation and characterization of imidazoline receptor protein from bovine adrenal chromaffin cells
45. 2-adrenoceptor and non adrenergic idazoxan-binding sites
46. Development of anti-idiotypic antibodies specific for the human cerebral imidazoline receptor
47. Isolation of a human cerebral imidazoline-specific binding protein
48. 2-adrenoceptors
49. Immunodetection of putative imidazoline receptor proteins in the human and rat brain and other tissues
50. +(ATP) channels in insulin-secreting cells
51. 2 sites
52. Imidazoline compound stimulate insulin release by inhibition of K(ATP) channels and interaction with the exocytotic machinery
53. 1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells
54. Isolation of an endogenous clonidine-displacing substance form rat brain
55. Isolation and partial purification of a clonidine displacing endogenous brain substance
56. An endogenous substance with clonidine-like properties: Selective binding to imidazole sites in the ventrolateral medulla
57. An endogenous, non-catecholamine clonidine antagonist increases mean arterial blood pressure
58. Agmatine: An endogenous clonidine displacing substance in the brain
59. Novel selective compounds for the investigation of imidazoline receptors
60. Rilmenidine
61. Moxonidine, a review of its pharmacology, and therapeutic use in essential hypertension
62. 1-imidazoline agonist moxonidine administered into the rostral ventrolateral medulla
63. Rilmenidine selectivity for imidazoline receptors in human brain
64. 1-imidazoline receptor: From binding site to therapeutic target in cardiovascular disease
65. Antiarrhythmic action of rilmenidine on adrenaline-induced arrhythmia via central imidazoline receptors in halothane-anesthetized dogs
66. Inhibition of centrally induced ventricular arrhythmias by rilmenidine and idazoxan in rabbits
67. Effect of moxonidine on arrhythmias induced by coronary artery occlusion and reperfusion
68. Pharmacological characterization of the imidazoline receptor which mediates inhibition of noradrenaline release in the rabbit pulmonary artery
69. Regression of left ventricular hypertrophy in hypertensive patients after a one-year treatment with rilmenidine: A double blind, randomised, controlled versus nifedipine study
70. Linksventrikulare hypertrophieregression unter eine therapie mit moxonidin
71. Suppressing sympathetic activation in congestive heart failure
72. + channels in mouse pancreatic β-cells
73. Characterization of new efaroxan derivatives for use in purification of imidazoline-binding sites
74. Rilmenidine normalizes fructose-induced insulin resistance and hypertension in rats
75. Sympathetic nervous system in salt-sensitive and obese hypertension: Amelioration of multiple abnormalities by a central sympatholytic agent